Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

6/30/2003 7:24:06 PM ET

GLOBAL PATH NOW SWISS MEDICA, ANNOUNCES NEW STOCK SYMBOL & CUSIP NUMBER

Toronto, Canada – Global Path Inc.’s previously announced name change to Swiss Medica, Inc. is now effective.

The name change was approved by written consent of the Board of Directors and the holders of a majority of the

outstanding common stock on May 15, 2003, and became effective after the market close on Friday, June 27,

2003.

Effective today Swiss Medica’s stock will begin trading under the new symbol SWME. The new CUSIP number for

Swiss Medica’s shares is 87089C 10 4.

It is not necessary for shareholders to exchange their share certificates for post-name change certificates.

However, a registered shareholder may, if they wish, exchange their share certificates for post-name change

certificates through Swiss Medica’s transfer agent:

Atlas Stock Transfer Corporation, 5899 South State Street, Salt Lake City, Utah, 84017, telephone 801 266

7151, facsimile 801 262 0907.

About Swiss Medica Inc.

Swiss Medica Inc. is focused on acquiring over-the-counter bioscience products with demonstrated competitive

advantages and increasing their revenues by focused sales and marketing efforts in selected distribution

channels including retail, direct sales, direct response, and e-commerce. Swiss Medica’s mission is to be a world

leader in the acquisition and commercialization of life enhancing bioscience products that improve quality of

lives. Please visit our website at www.swissmedica.com.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the

United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica’s services, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

Investor Relations Contact:

Dave Jones: 705 495 0022